What if a gas used in anesthesia became a weapon against Alzheimer's disease? A recent study reveals that xenon, a noble gas, ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

Taking longer to drift into the dreaming phase – known as rapid eye movement (REM) sleep – could be an early sign of Alzheimer's disease, potentially opening up new ways to diagnose and treat the ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.

An inert and unreactive gas may not seem like an obvious candidate for treating Alzheimer's disease, yet a new study in mice ...

People who exercise throughout their lives have a better chance of avoiding dementia - even if they show signs of diseases ...

Taking too long to enter the phase of sleep in which we dream may be an early sign of Alzheimer's disease. This is the ...

Delays in dreaming might be an early warning sign of Alzheimer’s disease.People who take significantly longer to ente ...

Drugs targeting amyloid plaques have failed to show efficacy in clinical trials. A new approach is needed to tackle AD ...